Viewing nowPregabalin Sublingual Tablet 150mg (Pregabalin)
Pregabalin 150mg
Orally disintegrating Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

MFDS item code 202600530 · Approved 2026.02.24
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures
This medication alleviates peripheral and central neuropathic pain in adults and is used as an adjunctive treatment for partial seizures in epilepsy patients. It also helps to improve symptoms of fibromyalgia. Overall, it is effective for neuropathic pain and seizure control.
Administer the total daily dose of pregabalin orally in 2 divided doses, with or without food. Place the tablet on the tongue and, once it disintegrates, swallow without water. Peripheral neuropathic pain — Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. Central neuropathic pain — Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. After an additional week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. Epilepsy — Adults: This drug may be administered at an initial dose of 150 mg per day. Depending on each patient's response and tolerability, the dose may be increased to 300 mg per day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg per day. The recommended dose of this drug for fibromyalgia is 300 mg-450 mg per day. The initial dose is 75 mg twice daily (150 mg per day); depending on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg per day). For patients who do not experience sufficient benefit at a dose of 300 mg per day, the dose may be increased within 1 week to 225 mg twice daily (450 mg per day). Clinical studies have also been conducted at a dose of 600 mg per day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg per day are not recommended. Based on current clinical experience, if treatment with this drug is discontinued, it should be withdrawn gradually over a period of at least 1 week. Patients with renal impairment: Dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance (CLcr), (mL/min) ≥60 — Initial dose 150 mg/day, maximum dose 600 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥30-<60 — Initial dose 75 mg/day, maximum dose 300 mg/day, BID or TID Creatinine clearance (CLcr), (mL/min) ≥15-<30 — Initial dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID Creatinine clearance (CLcr), (mL/min) <15 — Initial dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis — 25 mg, 100 mg, single dose This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, administer a supplemental dose promptly after each 4-hour hemodialysis session. TID = total daily dose divided into 3 doses BID = total daily dose divided into 2 doses QD = once daily a: The total daily dose (mg/day) should be divided as specified in the dosing regimen. b: A supplemental dose refers to an additional dose administered once. No dose adjustment is necessary in patients with hepatic impairment. Elderly patients (65 years and older): Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age — Administration is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12-17 years — Administration is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, if there are any changes in mood or behavior during use, medical personnel should be notified immediately. Patients with hypersensitivity to this medication should not take it. Diabetes patients may require dosage adjustments for blood sugar control due to weight gain. If symptoms of angioedema appear, usage should be discontinued immediately. Elderly patients should be cautious of falls or accidents due to dizziness or drowsiness. Blurred vision or changes in vision may occur, and these symptoms may improve upon discontinuation of the medication. If the medication is abruptly stopped, withdrawal symptoms such as insomnia, headache, and anxiety may occur; therefore, it should be gradually reduced in consultation with a doctor. There is a risk of drug abuse, so caution is needed in patients with a history of mental illness or drug abuse. Patients with reduced kidney function may need dosage adjustments. Patients with heart disease should use this medication with particular caution. Taking this medication with other CNS depressants may increase the risk of respiratory depression and other side effects. It is not recommended for use during the early stages of pregnancy due to the risk of fetal malformations unless special circumstances exist; women of childbearing age should use effective contraception. During lactation, the drug may be passed into breast milk, so nursing should be considered for discontinuation or cessation of the medication. Dizziness and drowsiness are common side effects, so driving or operating dangerous machinery after taking the drug should be avoided. Severe skin reactions may rarely occur; if symptoms such as skin rash or swelling appear, medication should be stopped immediately and medical consultation sought. In the case of overdose, symptoms may include confusion, drowsiness, and depression; treatment such as hemodialysis may be required if necessary. Keep this medication out of reach of children, and avoid transferring it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is crucial to maintain storage temperatures between 1 and 30 degrees Celsius to ensure the drug's effectiveness and safety.
Pink oval sublingual tablet
30 tablets/PTP [10 tablets/PTP x 3], 100 tablets/PTP [10 tablets/PTP x 10]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 150mg
Orally disintegrating Tablet · Prescription medication
Hanol Bio Pharma Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.